Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by PWIB123on Sep 17, 2022 8:41pm
105 Views
Post# 34969420

RE:RE:RE:Why a new lawyer on the payroll

RE:RE:RE:Why a new lawyer on the payrollI was thinking either replace Lafond or they anticipate being so busy with multiple, new programs that he'll need greater support.  Either is fine by me.

Wino115 wrote: Does make it easier to "off-load" Lafond --(the old "...position has changed and we don't need generalist, we need 3 specialists.  Thanks for your service kind gentleman..."  Lafond was not a PL hire and we've seen he likes to upgrade positions.  He can't have been happy with the rationale or appearance of his GC dumping shares at lows with potentially game-changing developments he's been touting. Just a bad signal all around, and I think PL knows this now.  


qwerty22 wrote:

You know you should put all this in an email and send it to Paul. You're probably right Paul probably hasn't asked himself if Lafond can't handle this. He'd need to be a genius like you to think of this stuff.


Maybe it signals an expansion of the trial . There was a threat of going into clinical sites in Europe I'd begun to assume that was on hold, maybe it's to do with a bunch of new sites coming online in the near future for phase 1b. Phase 2 would constitute a huge expansion and probably would need some preparation. I'm not saying Ph2 is on the horizon but maybe they see it coming down the road and the groundwork starts soon.

I'd say they are prep'ing for success and success means scaling up. They might fail and need to undo all this but that is how it goes.

 

Trogarzon wrote: Another thing, the hiring of a legal cousel for M&A stuff... can't Lafond do that.... can't they hire outside lawyer when and if they get an opportunity.  Why increase my overhead with a permanent lawyer.. everything they announce or do always has an odd feeling to it.  I find it odd to hire a layer when we already have Lafond... Sometimes it feels like having Justin Trudeau or Bidden throwin money around with off the wokeness in the world.

 

 





<< Previous
Bullboard Posts
Next >>